TriSalus Life Sciences, Inc. (TLSI)Healthcare | Medical Devices | Westminster, United States | NasdaqGM
4.83 USD
-0.10
(-2.028%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.83 |
Hot Take ↕ | Aug. 22, 2026, 3:42 a.m. EDT
The investment case for TriSalus is currently broken by a severe deterioration in both profitability and shareholder value. While the company boasts a 'strong buy' recommendation from analysts and a lofty $10 price target, these figures ignore the reality that the business is burning cash, posting operating losses exceeding 86%, and trading at a negative forward P/E. The market has already punished the stock with a nearly 50% decline over the last four years, driven by two consecutive years of negative annual returns. This multi-year decline signals that the market views the current fundamentals as insufficient to sustain the current valuation, regardless of the optimistic analyst targets. Compounding the distress are active legal investigations into the officers and directors, which introduce significant governance risk and potential liability. Furthermore, the stock is heavily shorted with a short ratio of 17, indicating deep skepticism among sophisticated investors. With no dividend to provide income and a balance sheet showing negative free cash flow, there is no margin of safety here; the stock appears to be a value trap where the low price reflects a fundamental failure of the business model rather than a bargain opportunity. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.101407 |
| AutoETS | 0.102025 |
| AutoTheta | 0.103081 |
| MSTL | 0.107679 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 7.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.453 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 525.588 |
| Revenue per Share | 0.901 |
| Market Cap | 297,405,312 |
| Forward P/E | -19.32 |
| Beta | 0.43 |
| Profit Margins | -62.59% |
| Website | https://trisaluslifesci.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.06395346 |
| Address1 | 6,272 West 91st Avenue |
| All Time High | 16.24 |
| All Time Low | 2.2 |
| Ask | 5.72 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 107,310 |
| Average Daily Volume3 Month | 303,842 |
| Average Volume | 303,842 |
| Average Volume10Days | 107,310 |
| Beta | 0.427 |
| Bid | 3.39 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.107 |
| City | Westminster |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.83 |
| Current Ratio | 5.348 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.2399 |
| Day Low | 4.7001 |
| Debt To Equity | 525.588 |
| Display Name | TriSalus Life Sciences |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -29,949,000 |
| Ebitda Margins | -0.66440004 |
| Enterprise To Ebitda | -9.534 |
| Enterprise To Revenue | 6.335 |
| Enterprise Value | 285,543,328 |
| Eps Forward | -0.25 |
| Eps Trailing Twelve Months | -1.31 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.6528 |
| Fifty Day Average Change | 0.17719984 |
| Fifty Day Average Change Percent | 0.03808456 |
| Fifty Two Week Change Percent | -6.3953457 |
| Fifty Two Week High | 7.95 |
| Fifty Two Week High Change | -3.12 |
| Fifty Two Week High Change Percent | -0.39245284 |
| Fifty Two Week Low | 2.2 |
| Fifty Two Week Low Change | 2.6299999 |
| Fifty Two Week Low Change Percent | 1.1954545 |
| Fifty Two Week Range | 2.2 - 7.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,794,600,000 |
| Float Shares | 49,499,205 |
| Forward Eps | -0.25 |
| Forward P E | -19.32 |
| Free Cashflow | -10,875,875 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 102 |
| Fullday Change | -0.0999999 |
| Fullday Change Percent | -2.0284 |
| Fullday Price | 4.83 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.85789 |
| Gross Profits | 38,671,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.33960998 |
| Held Percent Institutions | 0.35712 |
| Implied Shares Outstanding | 61,574,600 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado. |
| Long Name | TriSalus Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 297,405,312 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_119056665 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -57,249,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 303,562,778 |
| Number Of Analyst Opinions | 4 |
| Open | 4.94 |
| Operating Cashflow | -22,802,000 |
| Operating Margins | -0.86026 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 888 321 5212 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.83 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 4.93 |
| Price Hint | 4 |
| Price To Book | 45.140186 |
| Price To Sales Trailing12 Months | 6.5977173 |
| Profit Margins | -0.62586 |
| Quick Ratio | 4.721 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.0999999 |
| Regular Market Change Percent | -2.0284 |
| Regular Market Day High | 5.2399 |
| Regular Market Day Low | 4.7001 |
| Regular Market Day Range | 4.7001 - 5.2399 |
| Regular Market Open | 4.94 |
| Regular Market Previous Close | 4.93 |
| Regular Market Price | 4.83 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 79,973 |
| Return On Assets | -0.36753 |
| Revenue Growth | 0.017 |
| Revenue Per Share | 0.901 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 61,574,600 |
| Shares Percent Shares Out | 0.0616 |
| Shares Short | 3,790,922 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,564,595 |
| Short Name | TriSalus Life Sciences, Inc. |
| Short Percent Of Float | 0.081199996 |
| Short Ratio | 17.36 |
| Source Interval | 15 |
| State | CO |
| Symbol | TLSI |
| Target High Price | 14.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 9.5 |
| Total Cash | 46,288,000 |
| Total Cash Per Share | 0.752 |
| Total Debt | 34,426,000 |
| Total Revenue | 45,077,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.31 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.821875 |
| Two Hundred Day Average Change | 0.008124828 |
| Two Hundred Day Average Change Percent | 0.0016849935 |
| Type Disp | Equity |
| Volume | 79,973 |
| Website | https://trisaluslifesci.com |
| Zip | 80,031 |